Intercell Programs and Expertise Highlighted at World Vaccine Congress

VIENNA, April 22 /PRNewswire/ -- Intercell AG (VSE; "ICLL") today announced that members of the management team presented at the World Vaccine Congress on innovation, the company's Ixiaro® vaccine, and development and regulatory challenges, held April 19-22 near Washington, DC.  During the congress, on April 20, 2010, Dr. Gerd Zettlmeissl, chief executive officer, Intercell received a Vaccine Industry Excellence Award for Biotech CEO of the Year.

"It is a great honor to be recognized with a ViE award," commented Dr. Zettlmeissl. "Although named personally in the award, I believe it credits every Intercell employee, whose expertise, professionalism and daily efforts have allowed us to achieve this level of success."

As part of the Congress program, on April 19, Dr. David Venables, chief operating officer and site director of Intercell USA, Inc. made a podium presentation titled "Driving vaccine innovation through a combination of pipelines and alliances." He discussed how Intercell has positioned its pipeline to take full advantage of strategic partnerships as well as the company's own development and commercialization capabilities. Further, he presented Intercell's goals and vision for building the Company's strategic position in a growing marketplace.

On April 20, Jeff Hackman, senior vice president of commercial operations made the Company's second presentation at the Congress, titled "Ixiaro - Japanese Encephalitis vaccine development, surpassing clinical hurdles and approval." Hackman provided a broad overview of the Ixiaro vaccine and vaccination guidelines recommended by the Advisory Committee on Immunization Practices (ACIP). He underscored Intercell's commitment to serving the needs of diverse markets, including travelers and the military.

Two members of Intercell's staff also presented during expert panels at the meetings. On April 21, Dr. Gregory Glenn, senior medical officer, participated on a panel titled "what challenges remain amongst developing novel administration systems." Today, Dr. Kimber Poffenberger, senior vice president and global head of regulatory affairs, joined industry leaders on a panel titled "how can you align strategies with regulation to avoid barriers to vaccine development?"

The World Vaccine Congress is reportedly the longest-running and largest vaccine industry event in North America. For more information on the congress, please visit their website at http://www.terrapinn.com/2010/wvcdc/.

About Intercell AG

Intercell AG is an innovative biotechnology company that develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs. Intercell's vaccine to prevent Japanese Encephalitis is the Company's first product on the market.

The Company's technology platform includes an antigen-discovery system, adjuvants and a novel patch-based delivery system (Vaccine Patch, Vaccine Enhancement Patch). Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including GSK, Novartis, Merck & Co., Inc., sanofi-aventis, and Pfizer (formerly Wyeth).

The Company's pipeline of investigational products includes a Travelers' Diarrhea Vaccine Patch (Phase III), a Pseudomonas vaccine candidate (Phase II), a vaccine to prevent Pandemic Influenza combining our Vaccine Enhancement Patch with an injected vaccine (Phase II), a vaccine program for S. aureus, which is being developed with Merck & Co., Inc. (Phase II/III), as well as a vaccine candidate for Pneumococcus (Phase I). In addition, further products focused on infectious diseases are in pre-clinical development.

Intercell is listed on the Vienna stock exchange under the symbol "ICLL" (U.S. level one ADR symbol "INRLY").

For more information, please visit: www.intercell.com.

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SOURCE Intercell AG